CEO of WAVE Life Sciences, Paul Bolno, sold 48,366 shares at $5.78 each, totaling $279,575. WAVE focuses on genetic disease therapies. Insider transaction history shows more buying than selling. The stock is slightly overvalued according to GF Value.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing